EE+ POEM Archive
Neither aducanumab nor donanemab is cost-effective in treating adults with early Alzheimer disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Neither Aducanumab nor Donanemab Is Cost-effective in Treating Adults With Early Alzheimer Disease." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315637/all/Neither_aducanumab_nor_donanemab_is_cost_effective_in_treating_adults_with_early_Alzheimer_disease.
Neither aducanumab nor donanemab is cost-effective in treating adults with early Alzheimer disease. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315637/all/Neither_aducanumab_nor_donanemab_is_cost_effective_in_treating_adults_with_early_Alzheimer_disease. Accessed September 15, 2024.
Neither aducanumab nor donanemab is cost-effective in treating adults with early Alzheimer disease. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315637/all/Neither_aducanumab_nor_donanemab_is_cost_effective_in_treating_adults_with_early_Alzheimer_disease
Neither Aducanumab nor Donanemab Is Cost-effective in Treating Adults With Early Alzheimer Disease [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 September 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315637/all/Neither_aducanumab_nor_donanemab_is_cost_effective_in_treating_adults_with_early_Alzheimer_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Neither aducanumab nor donanemab is cost-effective in treating adults with early Alzheimer disease
ID - 1315637
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315637/all/Neither_aducanumab_nor_donanemab_is_cost_effective_in_treating_adults_with_early_Alzheimer_disease
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
